Yearly Archives: 2022

Halia Therapeutics, the first biotechnology company to target NEK7 to block the assembly of the NLRP3 inflammasome complex, participated today in a fireside chat exploring approaches to innovate Alzheimer’s therapies at InformaConnect’s Therapeutic Focus-Neurology digital conference. “There is very little help available for people suffering from neuroinflammatory diseases, such as Alzheimer’s (AD). We do know […]

Based on recently secured private payer and Medicaid insurance coverage contracts for KidneyIntelX, Renalytix plc is disclosing that the upper Midwest region of the United States, and specifically Illinois and Iowa, are now primary commercial expansion markets.  Private insurance coverage contracts secured and effective during the quarter ending September 30, 2022 include Blue Cross Blue […]

Nomi Health, a direct healthcare company dedicated to improving access and lowering costs in the healthcare system, has expanded its COVID vaccine services with the addition of the Novavax vaccine, now available at the West Valley Nomi Health location. In addition to Novavax, this location also distributes Pfizer, Moderna and Johnson & Johnson vaccines. All […]

Transit Scientific, a Utah-based medical device company, today announced additional U.S. patent protection has been issued from the United States Patent and Trademark Office (USPTO) for its XO exoskeleton sheath platform. Traditional PTA cutting, scoring, and constraining structure (CS) technologies are manufactured with metal or polymer wires, struts, blades, or grooves wrapped around, or fused to, the outside of the angioplasty balloon. These […]

After an all-night session, the Senate on Sunday passed a sweeping, $740 billion reconciliation package titled the “Inflation Reduction.” The measure passed on a party line 51-50 vote, with Vice President Kamala Harris breaking the tie vote. The 755-page bill will now be taken up by the House today, where it is expected to pass […]

98% of 401 Primary Care Physicians confirmed KidneyIntelX has value as a risk decision tool in their adult patients with type 2 diabetes and chronic kidney disease stages 1-3b. Published study complements KidneyIntelX clinical utility data published at American Diabetes Association Annual Conference demonstrating improvements in guideline recommended care, including therapeutic managements and specialist consultation […]

Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics has announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for DSP-5336, an investigational small molecule inhibitor against the binding of menin and mixed-lineage leukemia (MLL) protein, for the treatment of acute myeloid leukemia (AML).  “We are pleased to have […]